Table 2.

Plateau levels of hF.IX transgene expression and anti-hF.IX antibody formation at week 27

Animal no.	IS regimen	hF.IX, ng/mL	hF.IX, % of normal	Anti-hF.IX IgG, ng/mL	Bethesda titer, BU
1001	None	479	9.6	2000	0
1002	None	200	4.0	2500	0
1003	None	188	3.8	2300	0
2001	MMF, sirolimus, daclizumab	0	0	14172	1.1
2002	MMF, sirolimus, daclizumab	0	0	32224	215
2003	MMF, sirolimus, daclizumab	0	0	22027	45
3001	MMF, sirolimus	365	7.3	428	0
3002	MMF, sirolimus	242	4.8	2923	0
3003	MMF, sirolimus	240	4.8	8588	0